Progenics Pharmaceuticals Inc. (PGNX) Receives New Coverage from Analysts at Cantor Fitzgerald

Progenics Pharmaceuticals Inc. (PGNX) Receives New Coverage from Analysts at Cantor Fitzgerald


The brokerage issued an overweight rating and a $15.00 price objective on the biotechnology company's stock. Several other research analysts also recently issued reports on the stock.



from Biotech News